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Abstract. 
 
Migration, proliferation, and tube formation 
of endothelial cells are regulated by a protein kinase C 
isoenzyme PKC
 
u
 
. A full-length cDNA encoding a novel 
20-kD protein, whose expression was PKC
 
u
 
-depen-
dent, was identiﬁed in endothelial cells, cloned, charac-
terized, and designated as theta-associated protein 
(TAP) 20. Overexpression of TAP20 decreased cell ad-
hesion and enhanced migration on vitronectin and tube 
formation in three-dimensional culture. An antiintegrin 
 
a
 
v
 
b
 
5 antibody prevented these TAP20 effects. Overex-
pression of TAP20 also decreased focal adhesion for-
mation in 
 
a
 
v
 
b
 
3-deﬁcient cells. The interaction between 
TAP20 and 
 
b
 
5 integrin cytoplasmic domain was dem-
onstrated by protein coprecipitation and immunoblot-
ting. Thus, the discovery of TAP20, which interacts with 
integrin 
 
b
 
5 and modulates cell adhesion, migration, and 
tube formation, further deﬁnes a possible pathway to 
angiogenesis dependent on PKC
 
u
 
.
Key words: TAP20 • integrin • PKC
 
u 
 
• endothelial 
cells • migration
 
I
 
NTEGRIN
 
 receptors mediate the interactions between
cells and extracellular matrix (ECM),
 
1
 
 including en-
dothelial cell (EC) adhesion and migration, which are
required events for angiogenesis (Folkman and Shing,
1992; Hynes, 1992; Gumbiner, 1996; Clark and Hynes,
1997). Integrins are not only involved in cell adhesion but
also signal transduction. Signaling initiated through inte-
grin clustering and ligation with ECM-derived ligands has
been termed outside-in signaling, because it mobilizes in-
tracellular messengers. In contrast, in response to cyto-
plasmic signals, integrin conformation can be changed, re-
sulting in modulation of their ligand-binding affinity,
which is termed inside-out signaling (Schwartz et al.,
1995). Integrins in the 
 
b
 
1, 
 
b
 
2, 
 
b
 
3, and 
 
b
 
7 families have
been shown to exist in different ligand-binding affinity
states (Faull et al., 1993; Crowe et al., 1994; Shattil et al.,
1998). Integrin affinity modulation is initiated by intracel-
lular signals that change the affinity of integrins for their
ligands (Schwartz et al., 1995; Hughes and Pfaff, 1998).
This process involves the propagation of conformation
changes from the cytoplasmic domains to the extracellular
ligand-binding sites, resulting in an alteration of ligand-
binding affinity. The expression and analysis of recombi-
nant integrins in the cells demonstrate the importance of
the cytoplasmic domains for integrin affinity modulation
(Chen et al., 1992; Crowe et al., 1994; O’Toole et al., 1994,
1995; Wang et al., 1997). The cytoplasmic signaling path-
ways regulating integrin affinity are poorly understood;
however, several recent studies indicate that the Ras fam-
ily, Rho family, and phosphoinositide 3-kinase (PI3-kinase)
are involved in the regulation of integrin affinity (Lau-
danna et al., 1996; Zhang et al., 1996; Hughes et al., 1997;
Marte and Downward, 1997). There is increasing evidence
to suggest that integrin functions are modulated by intra-
cellular proteins that interact with integrin cytoplasmic do-
mains (Schwartz et al., 1995). Since integrin cytoplasmic
tails are crucial in the modulation of integrin affinity, pro-
teins that interact directly with the integrin cytoplasmic
tails are excellent candidates for modulators of integrin af-
finity. Interactions of integrins with the cytoskeleton via
talin and 
 
a
 
-actinin (Clark and Brugge, 1995; Lauffen-
burger and Horwitz, 1996), and with the focal adhesion
components, focal adhesion kinase (FAK) and paxillin
have been studied. These interactions may depend upon
ligand binding to regulate integrin affinity by stabilizing an
active conformation. However, recent evidence suggests
that interaction of the integrin cytoplasmic tail with the cy-
toskeleton can lock integrin in an inactive state (Kucik et
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1. 
 
Abbreviations used in this paper:
 
 EC, endothelial cell(s); ECM, extracel-
lular matrix; EGFP, enhanced GFP; FAK, focal adhesion kinase; FN, fi-
bronectin; HUVEC, human umbilical vein EC(s); GFP, green fluorescent
protein; GST, glutathione 
 
S
 
-transferase; LN, laminin; PKC, protein kinase
C; RCE, rat capillary endothelial cell(s); TAP, theta-associated protein;
VEGF, vascular endothelial growth factor; VN, vitronectin; wt, wild-type. 
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al., 1996; Stewart et al., 1998). A serine/threonine kinase
(pp59
 
ILK
 
) can bind to 
 
b
 
1, 
 
b
 
2, and 
 
b
 
3 tails and disrupt cell
adhesion, indicating a possible role in integrin modulation
(Hannigan et al., 1996). Binding of RACK1, the receptor
for activated protein kinase C (PKC), to the 
 
b
 
1, 
 
b
 
2, and 
 
b
 
5
cytoplasmic tails appears to depend upon stimulation with
phorbol esters (Liliental and Chang, 1998), indicating that
RACK1 could act as a link between PKC and integrins.
Integrin affinity modulation is a cell type– and integrin-
specific process; therefore, the interactions of integrins
with the abundant and integrin-nonspecific proteins dis-
cussed above may not definitively explain integrin affinity
regulation. Recently, several proteins interacting with spe-
cific integrin subunit cytoplasmic tails have been identi-
fied. 
 
b
 
3-endonexin, a novel 111-residue polypeptide that is
capable of binding the cytoplasmic tail of the 
 
b
 
3 integrin
subunit was identified by a yeast two-hybrid screening
strategy (Shattil et al., 1995; Eigenthaler et al., 1997; Kash-
iwagi et al., 1997). This polypeptide does not bind other in-
tegrin tails, including those of 
 
b
 
1, 
 
b
 
2, and 
 
a
 
IIb
 
. Transient
coexpression of integrin receptor 
 
a
 
IIb
 
b
 
3 and 
 
b
 
3-endonexin
in CHO cells revealed that 
 
b
 
3-endonexin can modulate
the affinity state of 
 
a
 
IIb
 
b
 
3 in a manner that is structurally
specific and subject to metabolic regulation. A 
 
b
 
2 integrin
cytoplasmic domain binding protein, cytohesin-1, has been
found to increase 
 
a
 
L
 
b
 
2-mediated cell adhesion (Kolanus
et al., 1996). Ca
 
2
 
1
 
- and integrin-binding protein (CIB) in-
teracts with the integrin 
 
a
 
IIb
 
 tail (Naik et al., 1997). Finally,
ICAP-1 (integrin cytoplasmic domain–associated protein-
1), interacts specifically with the 
 
b
 
1 integrin cytoplas-
mic domain (Chang et al., 1997). The effects of CIB and
ICAP-1 on integrin activation are not known.
Modulation of integrin function, in particular that of the
vitronectin (VN) receptors 
 
a
 
v
 
b
 
3 and 
 
a
 
v
 
b
 
5, is an important
process controlling angiogenesis. In vivo angiogenesis
models have defined two distinct angiogenic pathways: a
pathway using the 
 
a
 
v
 
b
 
3 integrin that mediates angiogene-
sis induced by fibroblast growth factor 2 or by tumor ne-
crosis factor 
 
a
 
; and a pathway initiated by vascular endo-
thelial growth factor (VEGF), transforming growth factor
 
a
 
, or PKC that is linked to integrin 
 
a
 
v
 
b
 
5 (Friedlander et al.,
1995). Our previous study (Tang et al., 1997) revealed that
selective inhibition of a specific member of the PKC fam-
ily, PKC
 
u
 
, prevents EC migration, proliferation, and tube
formation in vitro, thus raising the possibility that regula-
tion of EC function by PKC
 
u
 
 is accomplished by modula-
tion of 
 
a
 
v
 
b
 
5 function. One mechanism by which PKC
 
u
 
might regulate 
 
a
 
v
 
b
 
5 function is by controlling the expres-
sion of one or more integrin regulatory proteins.
 
Materials and Methods
 
Molecular Cloning
 
RNA display was performed using an RNAmap Kit (GenHunter) accord-
ing to the manufacturer’s instructions. The resulting PCR products were
cloned into plasmid pBluescript for sequencing analysis. To screen the rat
PC12 cDNA 
 
l
 
gt11 library (Clontech) for full-length theta-associated pro-
tein (TAP) 20, both the 5
 
9
 
 and 3
 
9
 
 insert screening amplimers of 
 
l
 
gt11 as
the forward primers and a TAP20 3
 
9
 
 end sequence ACCATAAGAATG-
CAGACAAGA as the reverse primer were used for PCR reaction with
pfu DNA polymerase (Stratagene). The PCR products were cloned
into the pBluescript plasmid (Stratagene) and sequenced with T7 and T3
primers.
 
Plasmids and Cell Culture
 
To explore the function of TAP20 in mammalian cells, we constructed a
TAP20 
 
1 
 
green fluorescent protein (GFP) expression plasmid. The
EGFP (enhanced GFP) gene from plasmid pEGFP-C1 (Clontech) includ-
ing its 5
 
9
 
 end cytomegalovirus (CMV) promoter to 3
 
9
 
 end polyA signal re-
gion, was inserted into the EcoRI-KpnI restriction sites (non-multicloning
sites) to create a GFP/pRc plasmid. TAP20 cDNA was then cloned into
the HindIII-XbaI restriction sites in the plasmid GFP/pRc. Thus, in this
vector the TAP20 and EGFP genes are controlled by separate CMV pro-
moters. To localize TAP20 protein in the cell, we cloned the TAP20
cDNA into the BglII-SmaI restriction sites in plasmid pEGFP-C1 for ex-
pression of a GFP-TAP20 fusion protein in mammalian cells.
ECV304 cells (a human bladder carcinoma cell line, distributed by
American Type Culture Collection) were cultured in M199 medium sup-
plemented with 10% FBS and antibiotics (GIBCO BRL), MV3 cells were
cultured in DMEM medium with 10% FBS and antibiotics, and human
umbilical vein ECs (HUVEC) were cultured in M199 with 20% newborn
calf serum, and 5% human serum, at 37
 
8
 
C in a humidified 5% CO
 
2
 
 atmo-
sphere. Monolayers of cells were transfected with either control vector or
TAP20 construct using lipofectin (GIBCO BRL) or GenePorter (Gene
Therapy System) for HUVEC. 1 d after transfection of GFP-containing
plasmids, cells were harvested and suspended in Hanks’ buffer (137 mM
NaCl, 5.4 mM KCl, 5.6 mM dextrose, 4.2 mM NaHCO
 
3
 
, 0.42 mM
Na
 
2
 
HPO
 
4
 
, 0.44 mM KH
 
2
 
PO
 
4
 
, pH 7.4), and were sorted by GFP fluores-
cence using a FACScan flow cytometer (Becton Dickinson). The sorted
cells were recultured in the complete medium. Expression of TAP20 was
confirmed by Western analysis using the anti-TAP20 antibody. The sorted
cells were tested in the cell adhesion, migration, and tube formation ex-
periments.
 
Northern Transfer Analysis
 
Total RNA was prepared using Trizol (GIBCO BRL). For Northern
transfer analysis, 20 
 
m
 
g of total RNA was subjected to electrophoresis on
a 1.5% formaldehyde-agarose gel and transferred to Gene-Screen Plus
membrane according to the manufacturer’s recommendations. The blot
was hybridized with random-primed TAP20 cDNA probes at 65
 
8
 
C for 3 h
in Quik-Hyb solution (Stratagene), and was washed under high stringency
conditions before autoradiography.
 
Immunoblotting
 
Immunoblotting was performed as follows: cell lysates were prepared by
addition of 1 ml of lysis buffer (PBS, 1% NP-40, 0.5% sodium deoxycho-
late, 0.1% SDS, 10 mg/ml PMSF, 30 ml/ml aprotinin) per 10
 
7
 
 cells. Sam-
ples were run on a 15 or 10% SDS polyacrylamide gel and electrophoreti-
cally transferred to Immobilon-P membranes (Millipore). The membranes
were then hybridized with indicated antibodies (anti-
 
a
 
v polyclonal anti-
body; Santa Cruz Biotechnology), PKC
 
u
 
, 
 
b
 
1, and 
 
b
 
3 mAb (Transduction
Laboratories), and anti-
 
b
 
5 polyclonal antibody (Chemicon), in PBS con-
taining 5% dry milk and detected via ECL (Amersham Pharmacia Bio-
tech). The affinity-purified rabbit polyclonal anti-TAP20 antibody was
produced by QCB Inc.
 
Adhesion Assay
 
Cell adhesion was performed as described previously (Giancotti and Ruo-
slahti, 1990; Leavesley et al., 1992) with minor modifications. In brief, 96-
well polystyrene plates (Costar) were coated with 10 
 
m
 
g/ml laminin (LN),
fibronectin (FN), or VN in PBS. Cells were harvested, suspended in me-
dium M199 (GIBCO BRL) with 2% BSA at a concentration of 100,000
cells/0.1 ml, and 50,000 cells were added to each well, with antibody as in-
dicated. After incubation at 37
 
8
 
C for 1 h, nonadherent cells were removed
with gentle washing. The cells in wells that were not washed were used as
the standard (100%). Quantitation of cell attachment was determined by
staining the cells with 0.5% crystal violet in 20% methanol, washing cells,
and then eluting the dye with 0.1 M sodium citrate, pH 4.2, and measuring
the absorbance at 596 nm. The integrin-blocking antibodies were pur-
chased from Chemicon.
 
Cell Migration Assay
 
The cell monolayer was briefly treated with trypsin to lift the cells, which
were pelleted and washed once with PBS and resuspended in M199 me-
dium containing 0.1% BSA to a final concentration of 500,000 cells/ml. 
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Cells were added to 3 
 
m
 
m FALCON Cell Culture FluoroBlok Inserts
(Becton Dickinson) at a density of 50,000 cells/insert. M199 (0.8 ml) with
10% FBS and VEGF (10 ng/ml) was used as a chemoattractant in the
lower wells. The inserts were incubated for 4 h at 37
 
8
 
C. The membranes of
the inserts were then mounted on glass slides and coverslips. Cells mi-
grated through the FluoroBlok Inserts were quantitated by counting the
fluorescent cells with a Nikon Optiphot-2 fluorescence microscope with a
COHU video camera (COHU Electronics) and NIH Image software for
Macintosh computer.
 
In Vitro Tube Formation
 
Matrix gel (MATRIGEL Basement Membrane matrix; Becton Dickin-
son) plates were prepared in 12-well plates following the manufacturer’s
instructions. After transfecting and sorting, HUVEC (
 
z
 
80% confluent)
were treated with trypsin, and 5 
 
3
 
 10
 
4
 
 cells were seeded on the top of
plates with complete M199 medium. The photographs were taken under a
100
 
3
 
 light microscope, monitoring with a COHU video camera, and cap-
tured with a Scion 7 video card (Scion Image) in a PowerMac computer.
 
Focal Adhesion
 
24 h after transfection with GFP alone, TAP20 
 
1 
 
GFP, or GFP-TAP20
plasmids, human MV3 (van Muijen et al., 1991, a gift from Dr. E. Danen,
NIH) cells were plated on 4-well glass chamber slides (Nalge Nunc)
coated with VN (10 
 
m
 
g/ml) (Sigma Chemical Co.). Cells were incubated
for the indicated times in DMEM containing 10% BSA, fixed with 4%
paraformaldehyde and 0.1% Triton X-100 in PBS for 5 min, and then
incubated with 4% paraformaldehyde in PBS for an additional 20 min.
Focal adhesions were visualized by incubating first with mouse mAb
against vinculin (1 
 
m
 
g/ml; Chemicon), paxillin (0.5 
 
m
 
g/ml; Transduction
Laboratories), or FAK (2 
 
m
 
g/ml, Transduction Laboratories), and then
with Cy-3–conjugated goat antibody to mouse IgG (dilution 1/600, Jack-
son ImmunoResearch Laboratories). Cells were viewed on a Nikon Op-
tiphot-2 fluorescence microscope and COHU video camera as described
above.
 
Glutathione S-Transferase Coprecipitation
 
The TAP20 cDNA was inserted into BamHI and XhoI cloning sites in
pGEX4T1 (Amersham Pharmacia Biotech). Cytoplasmic domains of inte-
grin 
 
b
 
3 (amino acid sequence: KLLITIHDRKEFAKFEEERARAKW-
FTANNPLYKEATSTFTNITYRGT) or 
 
b
 
5 (amino acid sequence:
KLLVTIHDRREFAKFQSERSRARYEMASNPLYRKPISTHTVDFT-
FNKFNKSYNGTVD) were synthesized by the PCR method using the
pfu enzyme and inserted into the BamHI and XhoI cloning sites. Glu-
tathione 
 
S
 
-transferase (GST) or GST fusion proteins were expressed in
 
Escherichia coli
 
 BL21 cells and immobilized on glutathione Sepharose
beads (Amersham Pharmacia Biotech) following the manufacturer’s in-
structions. To precipitate protein from EC lysate, the GST-TAP20 coated
beads were incubated with the cell lysate in PBS for 20 h at 4
 
8
 
C. To pre-
cipitate TAP20 with GST-integrin tail fusion protein, the GST-TAP20
beads were first incubated in thrombin containing buffer for 16 h at room
temperature to release the TAP20 protein. The TAP20-containing solu-
tion was then incubated with GST-integrin tail fusion protein beads for
20 h at 4
 
8
 
C. After three washes with PBS, the proteins bound to the beads
were eluted in 10 mM glutathione buffer and analyzed by Western blot-
ting. The antibodies used included: GST polyclonal antibody (Amersham
Pharmacia Biotech), 
 
a
 
v polyclonal antibody (Santa Cruz Biotechnology),
 
b
 
1 mAb and 
 
b
 
3 mAb (Transduction Laboratories), and 
 
b
 
5 polyclonal an-
tibody (Chemicon).
 
Results
 
Cloning of TAP20
 
We investigated the expression of genes regulated by
PKC
 
u
 
 with the mRNA display method (Liang and Pardee,
1992) using mRNAs from clonal populations of rat capil-
lary endothelial cells (RCE), in which either the kinase-
negative PKC
 
u
 
 (PKC
 
u
 
-kn, a dominant negative inhibitor)
or a constitutively active form of PKC
 
u
 
 (PKCu-ca) were
overexpressed (Tang et al., 1997). An RNA of z0.8 kb
Figure 1. Molecular cloning and analysis of TAP20. (A) Nucle-
otide and deduced amino acid sequence of TAP20. The deduced
amino acid sequence (single letter code) is shown under the nu-
cleotide sequence. The solid line indicates the sequence used as
the reverse primer to screen the rat PC12 library. The box indi-
cates the sequence of peptide used as an immunogen to induce
TAP20 antibody formation. (B and C) Differential expression of
TAP20 in RCE with varying PKCu activity levels. Total RNA
(B) and RCE lysate (C) were prepared from wt RCE (wt) or cells
stably expressing control plasmid (v), PKCu-ca (ca1 and ca2), or
PKCu-kn (kn1 and kn2). The full-length TAP20 cDNA was used
as probe on Northern blot (B), and the TAP20 antibody was used
for Western analysis (C). (D) Amino acid sequence comparison
of TAP20 with b3-endonexin. Identical amino acids are shown by
the letters in gray boxes. Lower case letters indicate additional 59
amino acids of the longer form of b3-endonexin, and the boxed
sequence indicates the immunogen peptide for TAP20.The Journal of Cell Biology, Volume 147, 1999 1076
whose expression depended upon the presence of active
PKCu was identified. Northern transfer analysis showed
that this 0.8-kb mRNA is highly expressed in PKCu-ca
RCE but is dramatically suppressed in PKCu-kn RCE
(Fig. 1 B). The partial sequence of this gene obtained from
differential display was used to screen a rat PC12 cDNA li-
brary by the PCR method. The cDNA generated from the
PCR was cloned, and the nucleotide sequence was deter-
mined (Fig. 1 A). The open reading frame encodes a novel
protein of 175 residues with a calculated molecular mass of
z20 kD. An antibody raised against the COOH terminus
of this putative protein recognized a protein of 20 kD (Fig.
1 C), as assessed by immunoblotting of an RCE cell lysate,
which confirmed that the expression of this protein de-
pended upon functional PKCu, as suggested by the North-
ern transfer analysis. In the PKCu kinase-negative RCE,
TAP20 expression was significantly decreased at the pro-
tein level. This anti-TAP20 antibody also recognized a 20-kD
band in TAP20 transfected human cells (Fig. 1 C and
Fig. 2), suggesting that TAP20 can be expressed as a
20-kD, full-length protein in the cells. Accordingly, this
novel PKCu-associated protein was designated TAP20. By
searching the GeneBank database, we found that a partial
39 end sequence of TAP20 had been reported previously
(Kerr et al., 1994), and the first 110 amino acid residues of
TAP20 share 55% homology with human b3-endonexin
(Shattil et al., 1995; Eigenthaler et al., 1997; Kashiwagi et
al., 1997), a 111-residue polypeptide that interacts with the
b3 integrin subunit (Fig. 1 D). TAP20 also has an
additional 66-residue COOH terminus. Thus, although
the differences suggest that TAP20 may have functional
properties that differ from those of b3-endonexin, we hy-
pothesized that TAP20 is involved in integrin-mediated
cell functions that are regulated by PKCu.
Expression of TAP20 and TAP20 Fusion Proteins in 
Human Cell Lines
The immunoblotting with the anti-TAP20 antibody that
recognizes an epitope at the COOH terminus of the pro-
tein suggests that TAP20 is expressed as a full-length pro-
tein in RCE. To explore the function of TAP20 in human
cells, TAP20 cDNA was cloned into the pRc/CMV vector
and a cDNA encoding GFP was inserted into a separate
region of the same plasmid; thus, these two cDNAs were
controlled by separate CMV promoters (Fig. 2 A). 1 d af-
ter transfection, human ECV304 or HUVEC cells were
sorted by GFP fluorescence using FACS®. Cells with GFP
expression were recultured for 1–2 d before experiments.
Cells were then harvested for cell adhesion, migration, and
tube formation experiments, and also for the protein ex-
pression test (Fig. 2, B and C). Blotting with anti-TAP20
antibody showed that the antibody does not detect antigen
in the 20-kD range in wild-type (wt) or GFP transfected
cells. The expression of TAP20 in unsorted TAP20 1 GFP
cells was 30–70% of the sorted cells, depending on the
transfection efficiency. Furthermore, the expression level
of PKCu, integrin av, b3, and b5 was not changed in the
TAP20 1 GFP expressed ECV cells compared with the
untransfected or GFP transfected cells (Fig. 2 B).
To investigate the TAP20 effect on focal adhesion and
to further characterize TAP20 distribution in the cells, ei-
Figure 2. Expression of TAP20 in human cell lines. (A) Plasmid
constructs. The EGFP gene with its 59 end CMV promoter to 39
end polyA signal region was inserted into pRc/CMV to create a
GFP/pRc plasmid (GFP). TAP20 cDNA then was cloned into the
multicloning site in the GFP/pRc vector. Thus, TAP20 and
EGFP cDNAs were controlled by separate CMV promoters.
This construct is designated as TAP20 1 GFP. TAP20 cDNA
was also cloned into plasmid pEGFP-C1 for expression of a GFP-
TAP20 fusion protein in mammalian cells, and designated as
GFP-TAP20. (B) Expression of TAP20 in human ECV cells. 1 d
after transfection, cells were sorted by GFP fluorescence using
FACS®. Cells with GFP expression were recultured for 1–2 d be-
fore preparing cell lysates. The lysate of unsorted cells was pre-
pared 2–3 d after transfection. Anti-TAP20, anti-PKCu, anti-b3,
and anti-b5 antibodies were used to detect protein expression.
Lane 1, wt untransfected cells (wt); lanes 2 and 4, GFP/pRc trans-
fected cells (GFP); lanes 3 and 5, TAP20 1 GFP/pRc transfected
cells (TAP20 1 GFP). (C) Expression of TAP20 or fusion pro-
tein GFP-TAP20 in human MV3, and expression of TAP20 in
HUVEC cells. Lysates of transfected MV3 and sorted HUVEC
cells were prepared as described above for immunoblotting, and
anti-TAP20 antibody was used to detect protein expression. Lane
1 and 5, wt untransfected cells (wt); lanes 2 and 6, GFP/pRc
transfected cells (GFP); lanes 3 and 7, TAP20 1 GFP/pRc trans-
fected cells (TAP20 1 GFP); and lane 4, GFP-TAP20/pRc trans-
fected cells (GFP-TAP20).Tang et al. TAP20/b5-Integrin Effects on Endothelial Cells 1077
ther the TAP20 1 GFP plasmid or the fusion protein
GFP-TAP20 plasmid was transfected into MV3 cells, a b3
integrin–deficient cell line. The transfection efficiency var-
ied from 20–40% in different experiments. 2 d after trans-
fection, the cells were harvested and tested for TAP20 ex-
pression. Similar to ECV cells, the anti-TAP20 antibody
did not detect antigen in the 20-kD range in nontrans-
fected or GFP transfected MV3 cells, whereas a 20-kD
band in the TAP20 1 GFP transfected cells and an z45-
kD band in the GFP-TAP20 transfected cells were recog-
nized, which indicated the expression of TAP20 and GFP-
TAP20 fusion protein, respectively (Fig. 2 C).
TAP20 Reduces EC Adhesion on VN
Transfected ECV cells were sorted by GFP fluorescence
using a FACScan flow cytometer and recultured for 1–2 d.
Adhesion of TAP20 1 GFP expressing cells to VN, but
not to FN and LN, was significantly attenuated (Fig. 3 A)
compared with that of either group of control cells, i.e., the
wt cells or the cells expressing GFP only (a mean of 33.7 6
5.1% of the added TAP20 1 GFP cells adhered to VN, in
contrast to 73.5 6 7.5% [wt] and 75.0 6 6.3% [GFP] of the
control cells, P , 0.01). This result indicates that TAP20
affects cell adhesion by modulating the VN receptors, i.e.,
the avb3 and/or avb5 integrins. To further investigate the
TAP20 effect on VN receptors, antiintegrin antibodies
were added to cells on VN-coated plates to block function
of the VN receptors. As a control to rule out nonspecific
effects of integrin ligation, an anti–a2b1 integrin (LN re-
ceptor) antibody, BHA2.1 was tested. The results ob-
tained with the anti–VN receptor antibodies were com-
pared with those with anti-a2b1 antibody (Fig. 3 B). The
anti–a2b1 integrin antibody BHA2.1 did not significantly
affect cell adhesion on VN (comparing the BHA2.1 group
of bars on Fig. 3 B with the VN group of bars on Fig. 3 A).
Furthermore, adhesion of TAP20 1 GFP cells on VN was
reduced in the presence of BHA2.1 (31.6 6 7.7% of added
cells) to an extent similar to that with cells on VN plates
without BHA2.1 antibody (Fig. 3 A; VN group of bars). In
the experiments with the anti–VN receptor antibodies, the
effects of the anti-avb3 antibody LM609 were compared
with those of the control antibody BHA2.1. The degree of
adhesion in the BHA2.1 group was used as basal (100%)
for comparison with that of the LM609 and P1F6 groups in
Fig. 3 B. LM609 caused a 50.3% reduction of adhesion of
TAP20 1 GFP cells, and also caused a 39.4% reduction in
the wt cells and a 43.4% reduction in GFP cells. The dif-
ference in the magnitudes of the reductions between
BHA2.1 and LM609 was not statistically significant among
the three groups (P . 0.5). In contrast, the anti-avb5 anti-
body P1F6 compared with the control antibody BHA2.1
caused only a 7.4% reduction of adhesion of the TAP20 1
GFP cells, but caused significant reduction in both groups
of the control cells (38.0 [wt] and 45.6% [GFP]). The mag-
nitude of the reductions between BHA2.1 and P1F6 was
significantly less in the TAP20 1 GFP cells than that seen
in either group of the control cells (P , 0.01). These ob-
servations suggest that in the TAP20 transfectants, the
avb3 integrin remains functional as a VN receptor, which
can be blocked by the anti-avb3 antibody LM609. On the
other hand, the VN receptor function of avb5 integrin was
attenuated by TAP20 overexpression. Thus, blockage of
avb5 in TAP20 transfectants by anti-avb5 antibody P1F6
did not further reduce cell adhesion on VN significantly,
whereas the adhesion of the control cells with normal
avb5 function was dramatically decreased by this anti-
avb5 antibody.
TAP20 Inhibits Focal Adhesion Formation
The results of adhesion with the integrin-blocking anti-
bodies suggested that TAP20 affects cell function through
the avb5 integrin. To further clarify the role of TAP20 on
avb5 integrin, we next examined the effect of TAP20 on
focal adhesion formation in MV3 cells (van Muijen et al.,
1991), which are avb3-negative human melanoma cells
and therefore have the avb5 integrin as the principal sur-
face receptor for VN. Thus, when the cells are cultured on
VN-coated plates, the focal adhesion formation is caused
chiefly by the interaction of avb5 integrin with VN. We
first investigated the cellular localization of TAP20. After
Figure 3. Inhibition of cell
adhesion by TAP20. Trans-
fected cells were sorted with
GFP fluorescence and recul-
tured for 1–2 d. Cells were
briefly treated with trypsin,
washed with PBS, and resus-
pended in M199 medium
with 2% BSA. Cells (50,000/
well) were allowed to adhere
to a 96-well plate coated with
LN, FN, or VN (A). Cells at-
tached to VN were further in-
vestigated with monoclonal
antiintegrin antibodies (10
mg/ml) as indicated: the anti-
avb3 antibody, LM609; anti-
avb5, P1F6, and as a control
for integrin ligation, an anti–a2b1 integrin antibody, BHA2.1 (B). The attached EC were quantified by the dye staining method. At-
tached cells are expressed as the percentage of the seeded cells. The values are means from four separate experiments. Error bars indi-
cate standard deviation; asterisk indicates P , 0.01, TAP20 transfected ECV (TAP20 1 GFP) versus either wt or GFP alone transfec-
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16 h of adhesion to VN, MV3 cells expressing either GFP
alone (Fig. 4 A, panels a and b) or TAP20 1 GFP (Fig. 4
A, panels c and d) were stained with anti-TAP20 antibody
that was visualized with a Cy-3–conjugated secondary an-
tibody (Fig. 4 A, panels b and d). The strong staining in
Fig. 4 A, panel d, suggests that TAP20 exists in transfected
cells as a full-length protein. The TAP20 fluorescence was
observed diffusely in the cytoplasm and the nucleus, which
was also demonstrated by GFP fluorescence of the cells
expressing the GFP-TAP20 fusion protein (Fig. 4 B, panel
a). When these cells were stained with antifocal adhesion
component antibodies (antivinculin shown in Fig. 4 B,
panel b) to visualize the focal adhesions, no strong colocal-
ization of GFP-TAP20 with focal adhesions was observed,
indicating a possibility that TAP20 might dissociate from
or interrupt focal adhesion during the cell adhesion pro-
cess. To characterize the effect of TAP20 on focal adhe-
sions, MV3 cells were transfected with either control GFP
plasmid or TAP 1 GFP plasmid and plated on VN-coated
chamber slides. GFP transfectants formed numerous focal
adhesions, as demonstrated by antibodies against vinculin,
paxillin, or FAK (Fig. 4 C). In TAP20 1 GFP transfected
Figure 4 (continues on facing page).Tang et al. TAP20/b5-Integrin Effects on Endothelial Cells 1079
cells, the number of focal adhesions was significantly re-
duced by 60–70% (Fig. 4 D), compared with those in wt or
GFP alone transfected MV3 cells.
TAP20 Enhances EC Migration on VN and Tube 
Formation on Matrix Gel
Next, we monitored the effects of TAP20 on cell migration
with a modified Boyden chamber assay (Fig. 5 A). Trans-
fected HUVEC cells were sorted by GFP fluorescence us-
ing a FACScan flow cytometer and recultured for 1–2 d.
50,000 cells were seeded on each chamber. There was no
significant difference in migration on an FN-coated mem-
brane between the untransfected cells, GFP sorted GFP-
expressing cells, and TAP20 1 GFP expressing cells.
Migration of cells on a VN-coated plate was markedly en-
Figure 4. TAP20 modula-
tion of focal adhesion forma-
tion on MV3 cells. 24 h after
transfection with the plas-
mids encoding GFP, TAP20 1
GFP, or the fusion protein
GFP-TAP20, respectively,
human MV3 cells were
seeded on 4-well glass cham-
ber slides coated with VN (10
mg/ml) and incubated in a
378C incubator for 16 h. Af-
ter fixation, cells were immu-
nostained with antibodies.
(A) Cells transfected with
GFP (panels a and b) or
TAP20  1  GFP (panels c and
d) were stained with anti-
TAP20 antibody. Cells were
visualized with GFP fluores-
cence (panels a and c) and
Cy-3 fluorescence (panels b and d). Cells expressing TAP20 were strongly stained.
The weak stain in TAP20-negative cells may be caused by nonspecific staining by
the antibody. (B) Cells expressing the GFP-TAP20 fusion protein were visualized
with GFP fluorescence (panel a) or were stained with antivinculin antibody and
visualized with Cy-3 fluorescence (panel b). (C) Cells expressing GFP (left pan-
els) or TAP20 1 GFP (right panels) were stained with antibodies against vinculin
(V), paxillin (P), or FAK (F). Arrowheads indicate focal adhesions. (D) Focal ad-
hesions were quantified by counting four cells for each staining. A relative value
was determined in which the number of focal adhesions in TAP20 1 GFP cells is
expressed as a percentage of those in control (GFP alone) cells, which were nor-
malized at 100%. Data are expressed as the mean 6 S.D. (error bars). Asterisk in-
dicates P , 0.01, TAP20 1 GFP transfectants (TAP20 1 GFP) versus GFP alone
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hanced by expression of TAP20 (640.4 6 78.8 [TAP20]
versus 395.2 6 36.2 [wt] and 377.2 6 65.6 [GFP]). This en-
hancement (TAP20 versus the controls) could not be
blocked by the control anti-a2b1 antibody, BHA2.1, or by
the anti-avb3 antibody, LM609, but it could be blocked by
the anti-avb3 antibody, P1F6 (Fig. 5 B).
Since TAP20 modulated cell adhesion and migration,
we asked whether overexpressing TAP20 would alter the
ability of cells to form tubes on matrix gel. When the GFP-
sorted HUVEC cells were cultured in matrix gel, a three-
dimensional matrix, tube formation by TAP20 1 GFP
transfectants was significantly enhanced (Fig. 6). By 6 h,
Figure 5. Modulation of cell
migration by TAP20. Trans-
fected HUVEC cells were
sorted with GFP fluorescence
and recultured for 1–2 d.
Cells were briefly treated
with trypsin and suspended in
medium containing 0.1%
BSA, with addition of anti-
bodies as indicated: anti-
a2b1, BHA2.1; anti-avb3,
LM609; and anti-avb3, P1F6.
Cells (50,000/0.1 ml) were
seeded in coated FluoroBlok
Insert precoated with either
FN (A) or VN (B). Cells
were incubated for 4 h at 378C. After fixation, migrated cells were visualized under a fluorescence microscope. Cells that had migrated
through the membrane of FluoroBlok Inserts were quantitated by counting the fluorescent cells in two random nonoverlapped 1003
view fields. (A) Data are expressed as the mean 6 S.D. (error bars) of four separate experiments. Asterisk indicates P , 0.01, TAP20
transfectants (TAP 1 GFP) versus GFP alone transfected cells by t test.
Figure 6. Enhancement of
HUVEC tube formation on
matrix gel by TAP20. Trans-
fected cells were sorted with
GFP fluorescence and were
seeded on top of the matrix
gel with complete M199 me-
dium. The photographs were
taken using light microscopy
(1003 view field) with a
video TV camera system, at
the timepoints indicated.Tang et al. TAP20/b5-Integrin Effects on Endothelial Cells 1081
tube structures were observed in the TAP20 1 GFP trans-
fectants, but not in the control GFP cells. The number of
tubes formed by TAP20 1 GFP transfectants appeared to
be dramatically increased at all timepoints compared with
that by the control cells.
TAP20 Interacts with the Cytoplasmic Domain
of b5 Integrin
The experimental evidence above suggested that the ef-
fects of TAP20 on cells were mediated by the avb5 inte-
grin VN receptor. Immunoblotting with anti–b5 integrin
antibody showed that the expression of the b5 integrin in
TAP20 transfectants was similar to that in the control cells
(Fig. 2 B). Therefore, we asked whether the effects of
TAP20 could result from direct interaction with the avb5
integrin. We used a GST-TAP20 fusion protein purified
with glutathione Sepharose beads to precipitate proteins
from cell lysate, and probed proteins bound to the com-
plexes with the antibodies against av, b1, b3, and b5 inte-
grin subunits. GST alone did not precipitate any protein
recognized by these antibodies. Only the b5 integrin sub-
unit was precipitated by the GST-TAP20 fusion protein
(Fig. 7 A). To further confirm the TAP20–b5 integrin in-
teraction, we used GST fusion proteins containing the cy-
toplasmic tail of either the b3 or b5 integrin subunit to
precipitate TAP20 protein from lysate of ECV cells trans-
fected with TAP20 1 GFP. Immunoblotting with anti-
TAP20 antibody demonstrated that TAP20 protein could
coprecipitate with the GST–b5 tail fusion protein (Fig. 7
B). To rule out an indirect interaction between the GST-
TAP20 protein and the b5 integrin complex, or between
the GST–b5 tail and the TAP20 protein complex, we then
used the GST-integrin tail fusion proteins to precipitate
purified TAP20 protein. The GST-TAP20 fusion protein
was first purified with glutathione Sepharose beads, and
then was digested with thrombin. After incubation of the
GST–integrin tail–coated glutathione Sepharose beads
with TAP20 released by thrombin, GST–b5 tail beads
were able to precipitate TAP20, as shown in immunoblot-
ting with TAP20 antibody (Fig. 7 C).
Discussion
In this study, we identified a cDNA that encodes a novel
20-kD, 176–amino acid protein in RCE. Several observa-
tions in this study suggest that TAP20 is involved in inte-
grin function in intact cells: (a) expression of TAP20 is de-
pendent on PKCu activity, which is required by RCE for
migration and proliferation (Tang et al., 1997); (b) overex-
pression of TAP20 in human ECV cells resulted in an at-
tenuation of cell attachment to VN and a decrease of focal
adhesion formation on VN-coated plates; (c) expression of
TAP20 in HUVEC cells resulted in an increase of cell mi-
gration on VN-coated plates, which can be blocked by an
antiintegrin b5 antibody, P1F6; (d) expression of TAP20
in HUVEC cells enhances tube formation on matrix gel;
and (e) the GST fusion protein coprecipitation study dem-
onstrated that TAP20 binds to the cytoplasmic domain of
the b5 integrin subunit.
b3-endonexin (Shattil et al., 1995) is the only gene
closely related to TAP20. The overall amino acid sequence
of TAP20 and the long form of b3-endonexin share 56%
Figure 7. Interaction of TAP20 with b5 integrin subunit. (A) Western analysis
of proteins from ECV lysate precipitated by immobilized GST (control) or
GST-TAP20 fusion protein. Antibodies used for the blots are indicated. Lane
1, ECV lysate alone; lane 2, cell proteins coprecipitated with GST alone; lane
3, cell proteins coprecipitated with GST-TAP20 fusion protein. Arrowheads
indicate the proteins detected. (B) Western analysis of TAP20 protein in ECV
cell lysate precipitated by GST-integrin tail fusion protein, using TAP20 anti-
body. Lane 1, the lysate of ECV cells transfected with TAP20 1 GFP; lane 2,
protein precipitated by GST–b3 tail fusion protein–coated beads from the cell
lysate described in lane 1; lane 3, protein precipitated by the GST–b5 tail fu-
sion protein–coated beads from the cell lysate described in lane 1. (C) Western
analysis of TAP20 protein precipitated by GST-integrin tail fusion protein, us-
ing TAP20 antibody. Lane 1, lysate from E. coli BL21 cells expressing GST-
TAP20 fusion protein; lane 2, purified GST-TAP20 fusion protein digested
with thrombin, precipitated by the GST–b3 cytoplasmic domain fusion pro-
tein–coated beads for 20 h; lane 3, TAP20 protein precipitated by GST–b5 cy-
toplasmic domain fusion protein–coated beads at 48C for 20 h.The Journal of Cell Biology, Volume 147, 1999 1082
homology, and thus, these two proteins are encoded by
two different genes. Because of different mRNA splicing,
there are two forms of b3-endonexin–related messages in
cells, but only the short form peptide has b3 integrin bind-
ing activity (Shattil et al., 1995). An anti-TAP20 polyclonal
antibody raised against a portion of the COOH terminus
sequence of TAP20 recognizes a 20-kD band that is identi-
cal to calculated molecular weight of TAP20, indicating
that a full-length form of TAP20 exists in cells. Overex-
pression of TAP20 in cells and the TAP20 binding experi-
ments provide evidence that the full-length TAP20 protein
can bind to the b5 integrin.
Our data show that overexpression of TAP20 in ECV
cells affects cell adhesion and migration on VN, but not on
other ECM proteins such as FN and LN, indicating that
TAP20 regulates the function of the av integrin family.
Furthermore, TAP20 effects were inhibited by a specific
avb5 integrin–blocking antibody P1F6, not by an anti-
avb3 antibody LM609, indicating that TAP20 may specifi-
cally interact with the avb5 integrin. A GST-TAP20 fusion
protein coprecipitated specifically with detergent-solubi-
lized b5 integrin from ECV cells, and thus the binding of
TAP20 to b5 integrin does not depend on the existence of
av. A GST–b5 tail fusion protein coprecipitated specifi-
cally with TAP20 protein, indicating that the TAP20 bind-
ing site is in the cytoplasmic domain of b5 integrin. Unlike
b3-endonexin, which binds the b3 integrin and increases
the aIIbb3 receptor affinity when overexpressed in CHO
cells (Kashiwagi et al., 1997), TAP20 interacts with the b5
integrin and negatively regulates avb5-based adhesion
and focal adhesion formation. Therefore, the effect of
TAP20 is to decrease the affinity of its associated integrin
receptor avb5 for its ligand VN. These effects also differ
from those of the avb5 blocking antibody P1F6, which
can prevent cell migration and angiogenesis initiated by
VEGF or PKC activation (Friedlander et al., 1995), pre-
sumably by blocking the outside-in component of the inte-
grin bidirectional signaling pathway (Klemke et al., 1994;
Shattil and Ginsberg, 1997). This discrepancy suggests that
TAP20 regulates EC functions by changing the inside-out
component of avb5 signaling and thus modulating the
functions of the avb5 integrin, indicating a different inte-
grin regulating mechanism. Formation of focal adhesions
requires ECM-integrin ligation and integrin clustering.
The decrease in focal adhesions in the TAP20-overex-
pressing cells could result from the attenuation of ECM–
b5 integrin ligation by TAP20. On the other hand, TAP20
may interfere with the interaction between b5 integrin and
the cytoskeleton, which is required for focal adhesion for-
mation. Perhaps as a result of decreased binding to VN,
TAP20 enhances EC migration and in vitro tube forma-
tion. It is also possible that, despite negative modulation of
b5 integrin function, TAP20 may upregulate recruitment
of other molecules needed for migration, for instance.
This study demonstrates that TAP20 requires enzymati-
cally active PKCu for its transcription. It is very likely that
TAP20 expression is PKC isoenzyme specific. Direct inter-
action of TAP20 with the cytoplasmic tail of the b5 inte-
grin subunit is at least one of the pathways by which PKCu
might modulate EC migration and tube formation. There-
fore, controlling TAP20 expression presents a mechanism,
alternative to direct protein phosphorylation (Lewis et al.,
1996), by which PKCs can regulate integrin function, and
thus angiogenesis.
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